Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) has appointed Edward Tilly to its Board of Directors, effective September 18, 2026. The appointment brings the Board size to eight directors.

Tilly will serve as an independent director and join the Audit Committee. He brings more than 35 years of experience in exchange operations, market structure, capital markets, and global regulatory engagement.

Executive Background

Tilly served as Chairman and CEO of CBOE Global Markets for a decade. During his tenure, he helped transform the company from a domestic options exchange into a diversified global market infrastructure operator. He oversaw the growth of its market capitalization from approximately US$2 billion to more than US$18 billion.

He led CBOE’s US$3.4 billion acquisition of BATS Global Markets and expanded the company’s operational footprint to six continents. From 2021 to 2023, he served as Chairman of the World Federation of Exchanges. He has held board seats at the Options Clearing Corporation and the National Stock Exchange.

Most recently, Tilly was CEO of Clear Street, a prime brokerage and financial infrastructure firm. He continues to serve on Clear Street’s Board of Directors.

Strategic Rationale

Tom Manning, Cresco Labs Chairman of the Board, highlighted Tilly’s expertise in public market infrastructure. Manning stated that as the federal landscape evolves and U.S. capital markets access opens to companies like Cresco Labs, Tilly’s perspective is critical for navigating strategic and financial opportunities.

Tilly commented that Cresco Labs has built a leading branded portfolio in U.S. cannabis and a retail platform that consistently outperforms its markets. He noted that this operating foundation positions the company well as access to U.S. capital markets broadens.

Company Overview

Cresco Labs aims to normalize and professionalize the cannabis industry through a consumer packaged goods approach to building national brands. The company operates Sunnyside dispensaries and distributes brands including Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s, and Remedi.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) closed its acquisition of PharmaCann Penn, LLC for an aggregate consideration of $50 million. The deal secures nine operational retail medical marijuana dispensaries in Pennsylvania, reinforcing Cresco’s market leadership in the second-largest US medical cannabis market.

The transaction positions Cresco as the number one retailer providing medical marijuana to patients across Pennsylvania. Combined with its existing position as the state’s leading wholesaler, the company aims to leverage scale and vertical integration to drive competitive advantages.

Transaction Structure

The purchase price of $50,000,000 was satisfied through a combination of cash and a seller note. The deal was executed on a cash-free, debt-free basis with a mutually agreed-upon normalized target level of working capital.

Charlie Bachtell, CEO of Cresco Labs, stated that the company is focused on deploying capital into opportunities that strengthen its competitive position and generate attractive long-term returns. He noted that pairing additional retail doors with scaled cultivation and wholesale operations reinforces Cresco’s role as a consolidator in core markets.

What the Numbers Show

The acquisition targets a market generating more than $1.1 billion in annual sales last year, according to Hoodie Analytics. By acquiring nine doors for $50 million, Cresco is paying approximately $5.56 million per dispensary. This entry cost allows the company to immediately capture revenue in a high-volume jurisdiction while consolidating its dual dominance in both wholesale distribution and retail sales within Pennsylvania.

Strategic Outlook

Cresco expects the transaction to be immediately accretive to revenue, margins, and cash flow. The company plans to leverage its existing infrastructure to integrate the new locations efficiently. This move aligns with Cresco’s broader mission to normalize the medical marijuana industry through a consumer packaged goods approach to brand building and retail experience.